“All good things must come to an end.” Please join us for our last-ever #LCSM Chat on Thursday December 2, 2021 at 5 pm Pacific. Take time to check in, reminisce & come together as a community one last time.
I’ve been a co-moderator for #LCSM Chat since shortly after it started in 2013. I must admit, it’s hard to see it end. I created its website. I wrote/posted most of its blogs. I worked with guests to create patient-friendly content. I’ve made many friends and connections. But it’s time for this to happen. It just represents a change in priorities–I have more than enough advocacy, writing, and personal projects to keep me busy.
Remember, the IASLC STARS Program is accepting applications for 2021 Patient Research Advocates through May 10! STARS aims to help lung cancer patient advocates evolve into research advocates. https://www.iaslc.org/patient-advocacy/stars
I am honored to be a presenter at the Collaboration for Outcomes using Social Media in Oncology (COSMO) online conference tomorrow, April 8.
I’m speaking in Session IV (Social Media in Oncology: A Multistakeholder Look) on a panel titled: “Patient Engagement in Social Media: When the Doctor is No Longer the Expert” at 1:40–2:20 pm Eastern Time. Registration for the two-day conference is FREE. Register here: https://lnkd.in/duYxM7e
TODAY! What are your bold predictions for innovations, policy changes, advocacy strategies & anything else in the prevention, detection, treatment of lung cancer & support of our community? Join moderator David Cooke, MD for #LCSM Chat on Twitter! Read more here:
The first case of COVID-19 in the USA was reported on 1/20/2020—over 9 months ago. Since then, the country has reported 9,860,558 cases and 237,113 deaths (per Johns Hopkins). As the weather becomes cooler and we spend more time indoors, the number of cases is rapidly accelerating in almost every state.
Given this surge, holiday gatherings and activities present a serious risk for virus transmission. On November 5, 2020, the #LCSM (Lung Cancer Social Media) Chat community on Twitter discussed ways to enjoy and celebrate the holidays safely during the pandemic. Chat participants included lung cancer patients, caregivers, advocates, physicians, and healthcare workers. The chat, which included links to many helpful resources, covered the following topics:
What have we learned over the past 8 months about how COVID-19 is transmitted?
How can people reduce the risk of COVID-19 during outdoor activities?
How can people reduce the risk of COVID-19 when travel is involved? What about travel to or from hot spots?
How safe is it to meet with family and friends who had COVID-19 and recovered?
How can people reduce the risk of COVID-19 for indoor activities (shopping, dining in restaurants, family gatherings, worship services, etc.)?
Chemist Jean Cui at #ASCO17 posters with #ALK & #ROS1 NSCLC patients who thrive on drugs she helped develop
As cancer patients and caregivers transform into active cancer advocates, they may think about attending medical conferences. On March 8, at 8 pm Eastern Time (5 pm PST), #LCSM Chat will discuss various aspects of cancer advocate participation in medical conferences.
Some reasons for cancer advocates to attend medical conferences are to:
Learn more about cancer and treatment options for cancer
Get details about new research
Meet the top doctors who treat their type of cancer
Support an advocacy organization’s outreach booth
Network with other advocates, as well as clinicians and researchers
Share an advocate’s perspective on a specific topic, sometimes as an invited speaker
As more advocates participate in conferences, the conference organizers, professional societies, and medical practitioners are coming to understand the benefits of including advocate voices in their programs. #LCSM Chat member Janet Freeman-Daily was recently interviewed by the International Association for the Study of Lung Cancer about her participation in conferences–read the resulting article here: Why Should Advocates Attend Academic Lung Cancer Conferences?
Tools exist to help advocates navigate cancer conferences and understand the content they will see:
RAN’s Focus on Research Scholar Program
Scholars participate in preparatory conference calls, virtual classroom (webinars), learning materials and mentoring for research advocates to improve skills and understanding of biomedical research, and attend the ASCO Annual Meeting.
International Association for the Study of Lung Cancer (IASLC) Travel Awards for World Conference on Lung Cancer (WCLC)
Provides travel grants to WCLC, which is held in a different international city each year—it will be in Toronto Canada September 2018.
Our moderator Janet Freeman-Daily (@JFreemanDaily) will lead our discussion using the following prompts:
T1: When a cancer patient/caregiver attends a medical conference, what are benefits to the patient/caregiver? Benefits to medical professionals? To the conference?
T2: If you have attended a medical conference in which patients/caregivers participated, what did you like most about that conference? (Pls state whether you attended as patient, caregiver, or med professional)
T3: If a cancer patient or caregiver wanted to attend a medical conference, which would you recommend for their first conference, and why?
T4: What tips would you give a cancer patient or caregiver for making the most of their conference experience?
T5: What programs help cancer patients and caregivers attend and/or afford conferences? Do you have experience with any of them?
We hope you’ll join our #LCSM Chat on Thursday 3/8 at 8 pm Eastern Time (5 pm Pacific). If you’re new to tweet chats, please read our primer “To Participate in #LCSM Chat.”
Lung cancer is a complicated disease. Diagnosing and treating complex cases can require skills that cross a variety of medical specialties. Larger medical centers and hospitals may decide to discuss complex cases in tumor boards that include physicians that represent a variety of medical specialties.
Our May 4, 2017, #LCSM Chat (at 8pm Eastern, 5pm Pacific) will focus on defining what a multidisciplinary tumor board (MTB) does, who is involved, and why MTB are important in the treatment of lung cancer.
A treatment planning approach in which a number of doctors who are experts in different specialties (disciplines) review and discuss the medical condition and treatment options of a patient. In cancer treatment, a tumor board review may include that of a medical oncologist (who provides cancer treatment with drugs), a surgical oncologist (who provides cancer treatment with surgery), and a radiation oncologist (who provides cancer treatment with radiation). Also called multidisciplinary opinion.
Some of the medical doctors with specialized training that might participate in an MTB are:
Medical Oncologist: specializes in diagnosing cancer and treating it with medicines
Pathologist: specializes in identifying diseases and conditions by studying abnormal cells and tissues.
Pulmonologist: specializes in the diagnosis and treatment of pulmonary (lung) conditions and diseases.
Radiation Oncologist: specializes in treating cancer with ionizing radiation
Radiologist: specializes in diagnosing and treating diseases and injuries using medical imaging techniques, such as x-rays, computed tomography (CT), magnetic resonance imaging (MRI), nuclear medicine, and positron emission tomography (PET)
Thoracic surgeon: specializes in the surgical diagnosis, staging and treatment of cancer in the thorax (chest)
Moderator @JFreemanDaily will lead our discussion using the following questions:
T1: What does a multidisciplinary tumor board (MTB) do? Why is it important in #lungcancer treatment?
T2: What types of #lungcancer cases can benefit by MTB review?
T3: Who should be involved in an MTB? What medical specialties are usually represented?
T4: How often does an MTB reach a consensus about diagnosis and treatment recommendations in #lungcancer?
T5: What can patients do if their hospital does not have an MTB? What is the role of telemedicine?
Please join us for this valuable discussion. If you’re new to tweet chats, this primer will help.
Hope you will join the lung cancer community tomorrow 11/17 at 8pm Eastern for the first-ever Lung Cancer Awareness Month Facebook Live event with the National Cancer Institute and the concurrent Lung Cancer Social Media (#LCSM) Chat on Twitter. We’ll be talking about immunotherapy and lung cancer clinical trials.
Wed 6/29: #Hcchat will conduct the official Moonshot chat (use both #Hcchat and #Moonshot hashtags) at noon Eastern Time on the topic “Will the Moonshot lead to the death of cancer?” This chat applies to all types of cancers. Special guest will be Vincent T. DeVita, Jr, MD, who was head of the NCI during Nixon’s Cancer Act and author of “The Death of Cancer.”
I’ll be tweeting from the @LUNGevity Twitter account (along with Dr. Upal Basu-Roy and Katie Brown) and my own account (@JFreemanDaily). If you want to find me or other tweeps at ASCO, please come to the Official ASCO Tweetup June 4th at 5:45pm in the McCormick Convention Center Plate Room (South Building, Level 2.5 Food Court). Hope to see you there!